Prognostic Factors of Hodgkin's Disease Recurrence: An Experience From a Tertiary Academic Center in Iran DOI Open Access
Sharareh Seifi,

Zahra Esfahani‐Monfared,

Adnan Khosravi

et al.

Cureus, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 14, 2024

Introduction Despite the favorable prognosis of Hodgkin's disease (HD), some patients experience recurrence. Therefore, determining recurrence prognostic factors is very crucial to identify at risk early relapse, maintain remission, and improve outcomes. Materials methods This retrospective cohort study enrolled HD National Research Institute Tuberculosis Lung Disease (NRITLD), Masih Daneshvari Hospital, between January 1, 2002, June 30, 2018. Demographic characteristics clinical outcomes, including response treatment, progression, survival data, were considered. Results Two hundred fifty enrolled. The mean age diagnosis was 30.03 years. female-to-male ratio 1.06:1. Eighty-five (34%) recurrences occurred within period, most occurring before three years initial diagnosis. progression-free (PFS) 18.4 months. In both univariate multivariate analyses, advanced stage (stage IV) significantly associated with shorter PFS (P=0.0001 P=0.004, respectively). Also, observed in presence bulky tumors (P=0.037/univariate analysis) high-risk International Prognostic Score (IPS) (P=0.030/multivariate analysis). Conclusion Our findings Iranian patient revealed that higher such as disease, IPS, which needs special attention. Close follow-up, especially after diagnosis, has a great importance detect relapse.

Language: Английский

Safety and efficacy of anti-CD30 CAR-T cell therapy in relapsed/refractory classic Hodgkin lymphoma: a systematic review and meta-analysis DOI Creative Commons
Fanqiao Meng, Michael Xiang, Yu Liu

et al.

BMC Cancer, Journal Year: 2025, Volume and Issue: 25(1)

Published: Jan. 14, 2025

Relapsed/refractory classic Hodgkin lymphoma (R/R cHL) remains challenging to treat, and anti-CD30 chimeric antigen receptor T (CAR-T) cell therapy may be effective. This meta-analysis investigates the efficacy safety of CAR-T for treating R/R cHL. A systematic literature search PubMed, Cochrane, Embase, ClinicalTrials.gov, Web Science databases was conducted until February 2024. The odds ratio (OR) with a 95% confidence interval (CI) analysed using Review Manager 5.4. Outcomes including overall response rate (ORR), complete (CR), partial (PR), progression-free survival (PFS), (OS), adverse events (AEs) were extracted meta-analysis. We used Methodological Index Non-Randomized Studies (MINORS) evaluate quality included literature. total 151 participants from 8 records included. Meta-analysis showed ORR CD30 cHL 57% (95%CI 0.36–0.76, P = 0.50), CR 34% 0.13–0.64, 0.29) PR 32% 0.15–0.55, 0.12). With median follow-up range 9.5 71.5 months, 1-year PFS 39% (95% CI 0.30–0.49, 0.04), OS 89% 0.65–0.97, 0.005). most common hematologic AE leukopenia (72%, CI: 0.50–0.87), non-hematological cytokine release syndrome (CRS) (43%, 0.14–0.76). grade ≥ 3 AEs 66% 0.06–0.98, I2 93%, 0.70), 0.07–0.78, 85%, 0.51) in neutropenia thrombocytopenia, respectively. All tolerable resolved treatment. Current evidence suggests that is effective safe worth considering as viable therapeutic option.

Language: Английский

Citations

0
Modified Endothelial Activation and Stress Index: A New Predictor for Survival Outcomes in Classical Hodgkin Lymphoma Treated with Doxorubicin-Bleomycin-Vinblastine-Dacarbazine-Based Therapy DOI Creative Commons
Fazıl Çağrı Hunutlu, Hikmet Öztop, Vildan Gürsoy

et al.

Diagnostics, Journal Year: 2025, Volume and Issue: 15(2), P. 185 - 185

Published: Jan. 14, 2025

Background: Although the cure rates of classical Hodgkin Lymphoma (cHL) are as high 90% using current treatment protocols, prognosis is poor for primary refractory patients. Thus, a biomarker that can predict patients with early progression at time diagnosis an unmet clinical need. Endothelial activation and stress index (EASIX) its variant modified EASIX (mEASIX) scoring system currently used prediction in hematologic malignancies. This study aimed to investigate prognostic value mEASIX score newly diagnosed cHL Methods: Data from 206 who underwent positron emission tomography (PET)-guided doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) therapy between January 2007 November 2023 were retrospectively analyzed. The was evaluated receiver operating characteristic (ROC) analysis, Cox regression Kaplan–Meier method, then compared standard risk assessment methods. Results: median age 33 years, rate advanced stage 67%. ROC analysis determined optimal cut-off 17.28, categorizing into mEASIXhigh (47%) mEASIXlow (53%) groups. 5-year progression-free survival (PFS) (60% vs. 84.3%) overall (OS) (79.6% 95.8%) significantly lower group (p < 0.001). Additionally, multivariate showed independent variables affecting PFS included nodular sclerosing subtype (HR: 0.4), bone marrow involvement 2.6), elevated 3.1). Independent variables, which had effect on OS (HR:3.8) higher IPS-3 scores (HR:1.9). Furthermore, (≥17.28) identified variable indicating disease (OR: 6.5). Conclusions: powerful easy-to-access marker detection cases.

Language: Английский

Citations

0
Hodgkin lymphoma of the parotid gland: A case report with literature review DOI Creative Commons

Aras J. Qaradakhy,

Rawa M. Ali,

Rebaz M. Ali

et al.

Acta Oto-Laryngologica Case Reports, Journal Year: 2025, Volume and Issue: 10(1), P. 18 - 25

Published: Feb. 18, 2025

Language: Английский

Citations

0
A Rare Case of Mixed cellularity classic Hodgkin lymphoma with Positive CXCL13 Expression in Tumor Cells DOI Creative Commons
Fanrong Liu, Xuan Yang

Research Square (Research Square), Journal Year: 2025, Volume and Issue: unknown

Published: March 4, 2025

Abstract Background Mixed cellularity classic Hodgkin lymphoma is quite common among the subtypes of lymphoma. In cases this disease, structure affected lymph nodes often shows varying degrees damage. Early - stage lesions mostly manifest as involvement interfollicular area, partial node involvement, and follicular atrophy. article, we report a specific case review literature related to condition. Case presentation A 29-year-old male presented with fever left lower abdominal pain. Upon physical examination, multiple swollen could be touched in his abdomen. To make clear diagnosis, biopsy was performed on relevant site. Through comprehensive immunohistochemical analysis results bone marrow smear, patient diagnosed Hodgkin's (Mixed type). After chemotherapy carried out for him immediately according ABVD protocol. It worth emphasizing that prominent feature positive expression CXCL13 tumor cells. Generally, only expressed helper T However, case, appearance patient's cells extremely unusual. an in-depth search previous literature, no similar reports have been found. This undoubtedly rare situation research field also provides new focuses exploration directions subsequent work. Conclusion demonstrates typical characteristics Notably, show expression. Although existing phenomenon relatively limited, based current understanding, it speculated there may precursor lesion between angioimmunoblastic cell finding not deepens our understanding but alerts us once detected, potential possibility disease should taken into consideration.

Language: Английский

Citations

0
Clinicopathological Features and Prognostic Factors of AIDS-Related Lymphoma: A Retrospective Single- Center Study DOI
YingLiang Ma, Jing Chang,

Yuxue Gao

et al.

Research Square (Research Square), Journal Year: 2025, Volume and Issue: unknown

Published: April 21, 2025

Abstract AIDS-related lymphoma (ARL) is a leading cause of mortality among people living with HIV (PLWH), characterized by distinct clinicopathological features and generally poor prognosis. However, comprehensive studies on ARL remain limited. This study aimed to evaluate the characteristics, immune status, EBV/HIV viral loads in PLWH diagnosed lymphoma, assess their prognostic significance. A retrospective analysis was conducted 130 cases between 2017 2024. The cohort included 56 Burkitt (BL), 51 diffuse large B-cell (DLBCL), 9 Hodgkin (HL), 8 plasmablastic (PBL), 6 T/NK cell patients. median age 39 years, 94.6% patients being male. 2-year overall survival (OS) rate 50.6%, HL showing highest (85.7%) BL lowest (43.8%). Univariate identified several factors significantly associated poorer OS non-Hodgkin (NHL), including CD4 + T count < 200 cells/µL, presence B symptoms, Eastern Cooperative Oncology Group (ECOG) performance status > 1, elevated lactate dehydrogenase (LDH), advanced stage, multiple extranodal involvements (all P 0.05). Multivariate revealed cells/µL (HR: 2.051, = 0.029) LDH 0.383, 0.005) as independent factors. In conclusion, NHL, particularly DLBCL, are prevalent PLWH. Severe immunodeficiency levels key contributing NHL.

Language: Английский

Citations

0
Epstein-Barr Virus-Associated B-cell Lymphoproliferative Disorders and Lymphomas: Diagnostic Overlaps and Defining Features DOI
Ashley K. Volaric, Yuri Fedoriw

Human Pathology, Journal Year: 2024, Volume and Issue: unknown, P. 105697 - 105697

Published: Nov. 1, 2024

Language: Английский

Citations

2
Prognostic Factors of Hodgkin's Disease Recurrence: An Experience From a Tertiary Academic Center in Iran DOI Open Access
Sharareh Seifi,

Zahra Esfahani‐Monfared,

Adnan Khosravi

et al.

Cureus, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 14, 2024

Introduction Despite the favorable prognosis of Hodgkin's disease (HD), some patients experience recurrence. Therefore, determining recurrence prognostic factors is very crucial to identify at risk early relapse, maintain remission, and improve outcomes. Materials methods This retrospective cohort study enrolled HD National Research Institute Tuberculosis Lung Disease (NRITLD), Masih Daneshvari Hospital, between January 1, 2002, June 30, 2018. Demographic characteristics clinical outcomes, including response treatment, progression, survival data, were considered. Results Two hundred fifty enrolled. The mean age diagnosis was 30.03 years. female-to-male ratio 1.06:1. Eighty-five (34%) recurrences occurred within period, most occurring before three years initial diagnosis. progression-free (PFS) 18.4 months. In both univariate multivariate analyses, advanced stage (stage IV) significantly associated with shorter PFS (P=0.0001 P=0.004, respectively). Also, observed in presence bulky tumors (P=0.037/univariate analysis) high-risk International Prognostic Score (IPS) (P=0.030/multivariate analysis). Conclusion Our findings Iranian patient revealed that higher such as disease, IPS, which needs special attention. Close follow-up, especially after diagnosis, has a great importance detect relapse.

Language: Английский

Citations

0